Legend Biotech Corporation
LEGN
$19.91
-$0.58-2.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 58.40% | 55.68% | 64.02% | 77.98% | 78.29% |
| Total Other Revenue | 98.36% | 97.22% | -- | -197.50% | -197.37% |
| Total Revenue | 59.53% | 56.38% | 64.01% | 74.75% | 74.76% |
| Cost of Revenue | 84.82% | 104.12% | 73.94% | 85.67% | 64.92% |
| Gross Profit | 44.38% | 31.25% | 58.07% | 68.30% | 81.24% |
| SG&A Expenses | 18.70% | 19.52% | 20.20% | 22.83% | 35.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 320.00% | 320.00% | -- | -- | -- |
| Total Operating Expenses | 30.69% | 31.78% | 25.10% | 26.34% | 22.47% |
| Operating Income | 74.34% | 43.18% | 54.88% | 45.35% | 41.39% |
| Income Before Tax | 81.51% | -19.78% | -78.79% | 35.58% | -6.02% |
| Income Tax Expenses | 67.70% | -34.13% | -24.70% | 545.58% | 1,127.25% |
| Earnings from Continuing Operations | 71.85% | -14.66% | -67.74% | 31.12% | -14.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 71.85% | -14.66% | -67.74% | 31.12% | -14.17% |
| EBIT | 74.34% | 43.18% | 54.88% | 45.35% | 41.39% |
| EBITDA | 78.54% | 44.93% | 56.37% | 46.35% | 41.74% |
| EPS Basic | 71.90% | -14.00% | -66.51% | 31.76% | -13.00% |
| Normalized Basic EPS | 80.81% | -22.33% | -82.57% | 37.53% | -3.26% |
| EPS Diluted | 70.46% | -16.11% | -68.39% | 31.55% | -12.90% |
| Normalized Diluted EPS | 80.44% | -19.83% | -77.95% | 36.38% | -4.65% |
| Average Basic Shares Outstanding | 0.95% | 0.77% | 0.83% | 0.84% | 0.90% |
| Average Diluted Shares Outstanding | -0.57% | -1.65% | -1.60% | 3.32% | 3.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |